DNAPrint Selects Proteos To Manufacture PT-401 For Preclinical Evaluation

Lake Harmony, PA -- DNAPrint Genomics, Inc. (OTC BB: DNAP) today announced that it has selected Proteos, Inc. to manufacture the first batch of its new therapeutic candidate PT-401 (Super EPO dimer) for pre-clinical testing.

"Proteos has 20 years of experience in protein and peptide chemistry and has proven its ability as a Contract Research Organization (CRO) dealing with biologically complex therapeutics," stated DNAPrint Chief Medical Officer Hector Gomez, M.D., Ph. D. "The selection of Proteos is the culmination of a competitive bidding process solicited by DNAPrint management. In addition, Proteos' staff has previously worked with erythropoietin (EPO), the simpler, monomer form of the drug that major pharmaceutical companies currently have on the market."

For more information visit http://www.vlcn.com/dnap61405.htm.

TheNewsWire Top Winners are Travelzoo Inc (Nasdaq: TZOO), Santarus Inc (Nasdaq: SNTS), drugstore.com inc (Nasdaq: DSCM), Optical Cable Corp (Nasdaq: OCCF), Airnet Communications Corp (Nasdaq: ANCC), Presidential Life Corp (Nasdaq: PLFE), Royale Energy Inc (Nasdaq: ROYL) and Diodes Inc (Nasdaq: DIOD).

TheNewsWire Top Losers are GigaMedia Ltd (Nasdaq: GIGM), US Energy Corp (Nasdaq: USEG), WPCS Intl Inc (Nasdaq: WPCS), Internet Initiative Japan Inc (Nasdaq: IIJI), Vivus Inc (Nasdaq: VVUS), Workstream Inc (Nasdaq: WSTM), Cardiodynamics International Corp (Nasdaq: CDIC) and Imperial Industries (Nasdaq: IPII).

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. The company has hired and paid $595.00 for the publication and circulation of this report. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity and no representation.

Contact:
C.P. Barry
Company: http://www.TheNewsWire.com
Phone: 1.888.478.7669
Source: TheNewsWire.com

This press release was issued through GroupWeb EmailWire.Com. For more information on press release distribution, go to http://www.emailwire.com.